Villalobos-Vargas M, Lozada-Alvarado S, Salas-Campos I, Valverde-Vindas A, Jaikel-Víquez D

Language: Spanish
References: 26
Page: 28-33
PDF size: 149.77 Kb.

ABSTRACT

Introduction and aims: N. dimidiatum is a dematiaceous fungus that causes different types of infections in humans. One of these is the onychomycosis, which consists of nail infections caused by fungi. In general, the frequency of N. dimidiatum is low; but it is described as an infection that responds poorly to the treatments available; to the extent that some authors considered it to be a virtually incurable disease.
Materials and methods: The in vitro susceptibility of 20 clinical isolates of N. dimidiatum was determined using the microdilution method M38-A, as described by the Clinical Laboratory and Standards Institute (CLSI). The final concentrations were: 0.13 – 64 µg/mL for amorolfine and terbinafine, 0.06 – 32 µg/mL for ciclopirox and 0.03 – 16 µg/mL for itraconazole.
Results: The minimal inhibitory concentration (MIC)₅₀ and MIC₉₀ were 0.50 and 0.75 µg/mL for amorolfine, 0.13 and 0.13 µg/mL for terbinafine, 1.00 and 1.50 µg/mL for ciclopirox and 0.75 and ≥ 16.00 µg/mL for itraconazole, respectively.
Conclusions: The most effective treatment, in vitro, against N. dimidiatum was terbinafine and the least effective itraconazole.

REFERENCES

1. Vázquez H, Mendoza C, Arenas R. Onicomicosis por Scytalidium sp. Revisión de infecciones por Scytalidium (scytalidiosis) a propósito de un caso de melanoniquia. Dermatol Rev Mex 2005; 49:168-173.

2. Machouart M, Menir P, Helenon R, et al. Scytalidium and scytalidiosis: what's new in 2012? J Mycol Med 2013; 23(1): 40-46.

3. Salcedo N, Cabrera S. Scytalidium spp. en piel y uñas. Reporte de casos en Santo

4. Domingo, República Dominicana, 2010-2014. VITAE. 2015; 61.

5. Crespo-Erchiga V, Martínez-García S, Martínez-Pilar L. Dermatomicosis por Scytalidium. Piel 2005; 20(10): 498-503.

6. de Magalhaes K, Machado C, Fonseca I, et al. Hongos filamentosos no dermatofitos: onicomicosis en cuatro pacientes infectados con el virus de la inmunodeficiencia humana. Rev Iberoam Micol 2008; 25:45-49.

7. Salas-Campos I, Gross-Martínez N. Agentes etiológicos de onicomicosis diagnosticadas en el laboratorio de micología médica de la Universidad de Costa Rica. Acta Med Costarric 2012; 54(2):114-118.

8. Salas-Campos I, Gross-Martínez N, Carrillo-Dover P. Onicomicosis por hongos fuliginosos. Acta Med Costarric 2009; 51(4): 241-244.

9. Carrillo-Muñoz AJ, Giusiano G, Cárdenas D et al., Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis. Int J Antimicrob Agents 2008; 31: 540-543.

10. Cantón E, Martín E, Espinel-Ingroff A. Capítulo 15, Métodos estandarizados por el CLSI para el estudio de la sensibilidad a los antifúngicos (documentos M27-A3, M38-A y M44-A). En: Pemán J, Martín-Mazuelos E, Rubio-Calvo MC, editores. Guía Práctica de Identificación y Diagnóstico en Micología Clínica. Bilbao, 2007; ISBN:978-84-611-8776-8. Disponible en: http://www.guia.reviberoammicol.com/Capitulo15.pdf

11. Lacroix C, de Chauvin M. In vitro activity of amphotericin B, itraconazole, voriconazole, posaconazole, caspofungin and terbinafine against Scytalidium dimidiatum and Scytalidium hyalinum clinical isolates. J Antimicrob Chemother 2008; 61:835- 837.

12. Clayton YM. Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br J Dermatol 1994; 130(43):7-8.

13. Harman S, Ashbee H, Evans, E. Testing of antifungal combinations against yeasts and dermatophytes. J Dermatolog Treat 2004; 15:104-107.

14. Bunyaratavej S, Leeyaphan C, Rujitharanawong C, et al., Efficacy of 5% amorolfine nail lacquer in Neoscytalidium dimidiatum onychomycosis. J Dermatolog Treat 2015; 27(4):1-22.

15. Gupta A, Kohli Y. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br J Dermatol 2003; 149(2):296- 305).

16. Guarro J, Pujol I, Aguilar C, et al. In vitro antifungal susceptibility of nondermatophytic keratinophilic fungi. Rev Iberoam Micol 2000; 17:142-147.

17. Rudramurthy S, Jatana M, Singh R, et al. In vitro antifungal activity of Indian liposomal amphotericin B against clinical isolates of emerging species of yeast and moulds, and its comparison with amphotericin B deoxycholate, voriconazole, itraconazole and fluconazole. Mycoses 2012; 56(1):39-46.

18. James J, Santhanam J, Lee MC, et al. In Vitro Antifungal Susceptibility of Neoscytalidium dimidiatum Clinical Isolates from Malaysia. Mycopathologia 2017; 182(3-4):305-313.

19. Carrillo-Muñoz A, Tur-Tur C, Hernández-Molina J, et al. Antifúngicos disponibles para el tratamiento de las micosis ungueales. Rev Iberoam Micol 2010; 27(2):49-56

20. Rosen T, Stein L. Antifungal drugs for onychomycosis: efficacy, safety, and mechanisms of action. Semin Cutan Med Surg 2016; 35(3S):S51-S55.

21. Cursi Í, Neves M, Orofino-Costa R, et al. Onycomychosis due to Scytalidium spp. A clinical and epidemiologic study at a University Hospital in Rio de Janeiro, Brazil. Ann Bras Dermatol. 2011; 86(4):689-693.

22. Cursi Í, Teixeira R, Brasil I, et al. Onychomycosis due to Neoscytalidium treated with oral terbinafine, ciclopirox nail lacquer and nail abrasion: A Pilot Study of 25 Patients. Mycopathologia 2013; 175: 75-82.

23. Bunyaratavej S, Prasertworonun N, Leevaphan C, et al. Distinct characteristics of Scytalidium dimidiatum and non-dermatophyte onychomycosis as compared with dermatophyte onychomycosis. J Dermatol 2015; 42:1-5.

24. Madrid H, Ruíz-Cendoya M, Cano J, et al. Genotyping and in vitro antifungal susceptibility of Neoscytalidium dimidiatum isolates from different origins. Int J Antimicrob Agents 2009; 34:351-354.

25. Farwa U, Abbasi A, Ali I, et al. Non-Dermatophyte moulds as pathogens of onychomycosis. J Coll Physicians Surg Pak 2011; 21(10):597-600.

26. Bueno J, Martínez C, Zapata B, et al. In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis. Clin Exp Dermatol 2009; 35:658-663